3Z Pharma

08/10/2025

Let’s meet at NLS days!
Our CSO and co-founder, Haraldur Þorsteinsson, will be attending Nordic Life Science Days next week in Gothenburg, Sweden.

04/06/2025

Karl Ægir Karlsson er framkvæmdastjóri 3Z sem í stuttu máli er fyrirtæki sem uppgötvar nýja notkun fyrir gömul lyf. 3Z spratt upp úr öflugu rannsóknarumhverfi innan tækni- og verkfræðideildar Háskólans í Reykjavík en Karl er doktor í taugavísindum og prófessor við verkfræðid...

20/06/2022

https://news.cision.com/3z-ehf/r/3z-closes--2-million-funding-for-preclinical-development-of-novel-adhd-and-insomnia-therapeutics-ide,c3588505?fbclid=IwAR1bMONuP31A7BdJwS38QLW1yKu6g3PFgOI9HjX69Tke6amqy1szsC-QuRc

14/08/2017

Ánægjulegt að geta deilt þessari frétt með ykkur!

„Þetta samstarf gjörbreytir öllu í framtíð þessa sprotafyrirtækis. Því fylgir fé og einnig viðurkenning á okkar starfi sem nýtist í frekari sölu,“ segir Karl Ægir Karlsson, einn af stofnendum rannsóknafyrirtækisins 3Z.

03/02/2017

3Z is hiring - are you our next key team player?

04/08/2016

A recent report by nordurskautid.is on our latest developments...

13/07/2015

We just launched a new website! Check it out!
http://3z.is/

3Z is a preclinical drug company focusing on the discovery of Central Nervous System (CNS) drugs. It provides pharmaceutical companies with expert services in high throughput screening of small molecule libraries for CNS effects

13/07/2015

Our team recently published a short communication on REM sleep correlates in adult zebrafish, view publication here:

http://www.sciencedirect.com/science/article/pii/S0166432815003460

Sleep is not a uniform phenomenon, but is organized in alternating, fundamentally different states, rapid eye movement sleep and non-rapid eye movement sleep. Zebrafish (Danio rerio) have recently emerged as an excellent model for sleep research. Zebrafish are well characterized in terms of developm…

03/06/2013

3Z Pharmaceuticals receives a grant from the Icelandic Technology Development fund. The grant (est. 30 million ISK) will be used to perform a high throughput drug screen of a 1200 compound small molecule library, acquired from Prestwick Chemical (France). The screen is aimed at identifying new chemicals that modify sleep and wake behavior. Work on this project has already started.

03/04/2013

3Z and Prestwick Chemical announce a formal research collaboration! See press release here:
http://www.3z.is/3z-and-prestwick-chemical-announce-formal-research-collaboration/

20/09/2012

3Z recently published a profile in Public Service Review: Europe: Issue 24

http://www.3z.is/wp-content/uploads/2012/09/Profile.pdf